Marktanalyse - Hypertriglyceridemia - Pipeline Review, H2 2016

Global Markets Direct
113 Seiten

  • Europa
  • Asien / Pazifik
  • Mittlerer Osten / Afrika
  • Nordamerika / USA
  • Australien
  • Mittel- / Südamerika

Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:

PDF-Datei per E-Mail, Single User Price, versandkostenfrei
PDF-Datei per E-Mail, Site License Price**, versandkostenfrei
PDF-Datei per E-Mail, Enterprisewide Price (Global Site License)***, versandkostenfrei

Hinweise: **The report can be shared by users within one office (one geographical location) ***Across Geographical locations (by the purchasing company only)

Hypertriglyceridemia - Pipeline Review, H2 2016


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypertriglyceridemia — Pipeline Review, H2 2016, provides an overview of the Hypertriglyceridemia (Metabolic Disorders) pipeline landscape.

Hypertriglyceridemia is a condition in which triglyceride levels are elevated. Causes include diabetes mellitus, obesity, family history and sedentary habits. Symptoms include gastrointestinal pain, difficulty breathing, memory loss, dementia, xanthelasmas and corneal arcus. Treatment includes diuretics, beta-blockers, estrogen therapy and corticosteroids.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypertriglyceridemia — Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hypertriglyceridemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hypertriglyceridemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypertriglyceridemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 9, 1, 2, 11 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Hypertriglyceridemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


- The pipeline guide provides a snapshot of the global therapeutic landscape of Hypertriglyceridemia (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Hypertriglyceridemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hypertriglyceridemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hypertriglyceridemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hypertriglyceridemia (Metabolic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hypertriglyceridemia (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hypertriglyceridemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Hypertriglyceridemia Overview 9

Therapeutics Development 10

Pipeline Products for Hypertriglyceridemia - Overview 10

Pipeline Products for Hypertriglyceridemia - Comparative Analysis 11

Hypertriglyceridemia - Therapeutics under Development by Companies 12

Hypertriglyceridemia - Therapeutics under Investigation by Universities/Institutes 14

Hypertriglyceridemia - Pipeline Products Glance 15

Late Stage Products 15

Clinical Stage Products 16

Early Stage Products 17

Hypertriglyceridemia - Products under Development by Companies 18

Hypertriglyceridemia - Products under Investigation by Universities/Institutes 19

Hypertriglyceridemia - Companies Involved in Therapeutics Development 20

Acasti Pharma Inc 20

Akcea Therapeutics Inc 21

Allergan Plc 22

Alnylam Pharmaceuticals Inc 23

Arisaph Pharmaceuticals Inc 24

AstraZeneca Plc 25


Cardax Inc 27

Catabasis Pharmaceuticals Inc 28

Celon Pharma SA 29

CymaBay Therapeutics Inc 30

Gemphire Therapeutics Inc 31

Jeil Pharmaceutical Co Ltd 32

Kyorin Pharmaceutical Co Ltd 33

LipimetiX Development Inc 34

Matinas BioPharma Holdings Inc 35

Sancilio & Company Inc 36

Zydus Cadila Healthcare Ltd 37

Hypertriglyceridemia - Therapeutics Assessment 38

Assessment by Monotherapy Products 38

Assessment by Target 39

Assessment by Mechanism of Action 41

Assessment by Route of Administration 43

Assessment by Molecule Type 45

Drug Profiles 47

AEM-28 - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

AEM-2814 - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

ALN-AC3 - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

ALN-ANG - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

Antibody to Inhibit ANGPTL4 for Hypertriglyceridemia - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

ARI-3037MO - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

bezafibrate SR - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

BioE-1115 - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

BSN-272 - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

CAT-2000 Series - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

CAT-2003 - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

CDX-085 - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

gemcabene calcium - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

icosabutate - Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

IONIS-ANGPTL3LRx - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

IONIS-APOCIIILRX - Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

LTPO-3FA - Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

MAT-9001 - Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

MN-002 - Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

NKPL-66 - Drug Profile 75

Product Description 75

Mechanism Of Action 75

R&D Progress 75

omega-3-carboxylic acids - Drug Profile 79

Product Description 79

Mechanism Of Action 79

R&D Progress 79

saroglitazar - Drug Profile 83

Product Description 83

Mechanism Of Action 83

R&D Progress 83

SC-401 - Drug Profile 85

Product Description 85

Mechanism Of Action 85

R&D Progress 85

seladelpar - Drug Profile 86

Product Description 86

Mechanism Of Action 86

R&D Progress 86

Small Molecule for Hypertriglyceridaemia - Drug Profile 89

Product Description 89

Mechanism Of Action 89

R&D Progress 89

Synthetic Peptides for Dyslipidemic and Vascular Disorders - Drug Profile 90

Product Description 90

Mechanism Of Action 90

R&D Progress 90

volanesorsen sodium - Drug Profile 91

Product Description 91

Mechanism Of Action 91

R&D Progress 91

Hypertriglyceridemia - Dormant Projects 97

Hypertriglyceridemia - Discontinued Products 99

Hypertriglyceridemia - Product Development Milestones 100

Featured News & Press Releases 100

Dec 19, 2016: Akcea and Ionis Announce Positive Results from COMPASS Phase 3 Study of Volanesorsen 100

Sep 14, 2016: Acasti Pharma Reports Positive CaPre Omega-3 Bridging Study Data 101

Jun 11, 2016: New Scientific Data of Investigational Lipaglyn (Saroglitazar), and Real World Data in Patients will be Featured at American Diabetes Association (ADA) 76th Scientific Sessions 102

May 16, 2016: Akcea Therapeutics Announces Completion of Enrollment in Phase 3 COMPASS Trial of Volanesorsen 103

Mar 23, 2016: MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia 103

Feb 24, 2016: SPCI Announces US PTO Allowance of Patent Claims 104

Nov 18, 2015: Zydus announces clinical trials of Saroglitazar in patients with Severe Hypertriglyceridemia in USA 104

Jul 29, 2015: Positive Clinical Data From Volanesorsen Published in the New England Journal of Medicine 105

May 25, 2015: Phase 2a Clinical Study of Icosabutate in Patients with Severe Hypertriglyceridemia 106

Apr 22, 2015: CymaBay Therapeutics Announces U.S. Orphan Drug Designation for MBX-8025 in Severe Hypertriglyceridemia 107

Mar 02, 2015: Acasti Receives Full Data for Phase II TRIFECTA Trial 107

Sep 30, 2014: Acasti Announces Positive Top-Line Pharmacokinetic Results 108

Sep 29, 2014: Acasti Reports Successful CaPre Phase II TRIFECTA Results Proving Statistically Significant Improvements in Triglycerides & Non-HDL-C 108

Sep 02, 2014: Isis Pharmaceuticals Presents Data On ISIS-APOCIIIRX At European Society of Cardiology Congress 2014 110

Jul 24, 2014: Acasti Announces Oral Presentation on COLT Study Results at 19th World Congress on Heart Disease in Boston 110

Appendix 112

Methodology 112

Coverage 112

Secondary Research 112

Primary Research 112

Expert Panel Validation 112

Contact Us 112

Disclaimer 113

List of Tables

Number of Products under Development for Hypertriglyceridemia, H2 2016 10

Number of Products under Development for Hypertriglyceridemia - Comparative Analysis, H2 2016 11

Number of Products under Development by Companies, H2 2016 13

Number of Products under Investigation by Universities/Institutes, H2 2016 14

Comparative Analysis by Late Stage Development, H2 2016 15

Comparative Analysis by Clinical Stage Development, H2 2016 16

Comparative Analysis by Early Stage Development, H2 2016 17

Products under Development by Companies, H2 2016 18

Products under Investigation by Universities/Institutes, H2 2016 19

Hypertriglyceridemia - Pipeline by Acasti Pharma Inc, H2 2016 20

Hypertriglyceridemia - Pipeline by Akcea Therapeutics Inc, H2 2016 21

Hypertriglyceridemia - Pipeline by Allergan Plc, H2 2016 22

Hypertriglyceridemia - Pipeline by Alnylam Pharmaceuticals Inc, H2 2016 23

Hypertriglyceridemia - Pipeline by Arisaph Pharmaceuticals Inc, H2 2016 24

Hypertriglyceridemia - Pipeline by AstraZeneca Plc, H2 2016 25

Hypertriglyceridemia - Pipeline by BASF SE, H2 2016 26

Hypertriglyceridemia - Pipeline by Cardax Inc, H2 2016 27

Hypertriglyceridemia - Pipeline by Catabasis Pharmaceuticals Inc, H2 2016 28

Hypertriglyceridemia - Pipeline by Celon Pharma SA, H2 2016 29

Hypertriglyceridemia - Pipeline by CymaBay Therapeutics Inc, H2 2016 30

Hypertriglyceridemia - Pipeline by Gemphire Therapeutics Inc, H2 2016 31

Hypertriglyceridemia - Pipeline by Jeil Pharmaceutical Co Ltd, H2 2016 32

Hypertriglyceridemia - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2016 33

Hypertriglyceridemia - Pipeline by LipimetiX Development Inc, H2 2016 34

Hypertriglyceridemia - Pipeline by Matinas BioPharma Holdings Inc, H2 2016 35

Hypertriglyceridemia - Pipeline by Sancilio & Company Inc, H2 2016 36

Hypertriglyceridemia - Pipeline by Zydus Cadila Healthcare Ltd, H2 2016 37

Assessment by Monotherapy Products, H2 2016 38

Number of Products by Stage and Target, H2 2016 40

Number of Products by Stage and Mechanism of Action, H2 2016 42

Number of Products by Stage and Route of Administration, H2 2016 44

Number of Products by Stage and Molecule Type, H2 2016 46

Hypertriglyceridemia - Dormant Projects, H2 2016 97

Hypertriglyceridemia - Dormant Projects (Contd..1), H2 2016 98

Hypertriglyceridemia - Discontinued Products, H2 2016 99

List of Figures

Number of Products under Development for Hypertriglyceridemia, H2 2016 10

Number of Products under Development for Hypertriglyceridemia - Comparative Analysis, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Comparative Analysis by Clinical Stage Development, H2 2016 16

Comparative Analysis by Early Stage Products, H2 2016 17

Assessment by Monotherapy Products, H2 2016 38

Number of Products by Top 10 Targets, H2 2016 39

Number of Products by Stage and Top 10 Targets, H2 2016 39

Number of Products by Top 10 Mechanism of Actions, H2 2016 41

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 41

Number of Products by Routes of Administration, H2 2016 43

Number of Products by Stage and Routes of Administration, H2 2016 43

Number of Products by Molecule Types, H2 2016 45

Number of Products by Stage and Molecule Types, H2 2016 45

* Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.



Branchenwissen an zentraler Stelle bündeln und abrufbar machen – das ist das Hauptanliegen von Unser breites Informationsangebot rund um die Marktforschung richtet sich sowohl an Marktforschungsinstitute, Felddienstleister, Panelbetreiber und Herausgeber von Studien, Marktdaten sowie Marktanalysen als auch an deren Kunden aus Industrie, Handel und Dienstleistungsgewerbe.

facebook twitter google plus